Genetic tests showed that certain patients were predisposed to brain injuries if they took the drugs. That information remained secret.
Category: Leqembi (Drug)
-
New Drug Approved for Early Alzheimer’s
The drug, Kisunla, made by Eli Lilly, is the latest in a new class of treatments that could modestly slow cognitive decline in initial stages of the disease but also carry safety risks.
-
Advisory Panel of Experts Endorses F.D.A. Approval of New Alzheimer’s Drug
The modest benefits of the treatment, donanemab, made by Eli Lilly, outweigh the risks, the panel concluded unanimously.
-
Study Suggests Genetics as a Cause, Not Just a Risk, for Some Alzheimers
People with two copies of the gene variant APOE4 are almost certain to get Alzheimer’s, say researchers, who proposed a framework under which such patients could be diagnosed years before symptoms.
-
Treating Alzheimer’s Very Early Offers Better Hope of Slowing Decline, Study Finds
A trial of donanemab, an experimental drug, found it modestly slowed the worsening of memory and thinking and worked better in patients at earlier stages and those under 75.